63.49

3.67% 2.22

Livanova Plc (LIVN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$61.27

Offen:

$61.86

24-Stunden-Volumen:

865.48K

Relative Volume:

1.17

Marktkapitalisierung:

$3.47B

Einnahmen:

$1.39B

Nettoeinkommen (Verlust:

$-242.49M

KGV:

-14.18

EPS:

-4.4759

Netto-Cashflow:

$173.29M

1W Leistung:

+1.80%

1M Leistung:

-10.03%

6M Leistung:

+21.27%

1J Leistung:

+61.71%

1-Tages-Spanne:

$60.35

$64.01

1-Wochen-Bereich:

$60.35

$64.88

52-Wochen-Spanne:

$32.48

$71.92

Livanova Plc Stock (LIVN) Company Profile

Firmenname

Livanova Plc

Sektor

Healthcare (1115)

Branche

Medical Devices (143)

Telefon

4402033250662

Adresse

20 EASTBOURNE TERRACE, LONDON

Mitarbeiter

3,300

Twitter

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

LIVN's Discussions on Twitter

Compare LIVN vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LIVN Livanova Plc	63.51	3.35B	1.39B	-242.49M	173.29M	-4.4759
ABT Abbott Laboratories	102.54	177.03B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	327.84	124.89B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	86.53	110.08B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	62.49	93.53B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	79.96	45.84B	6.07B	1.06B	1.34B	1.8063

Livanova Plc Stock (LIVN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-19	Eingeleitet	KeyBanc Capital Markets	Overweight
2025-10-01	Herabstufung	Goldman	Buy → Neutral
2025-05-20	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-10-04	Eingeleitet	Goldman	Buy
2024-09-17	Hochstufung	Robert W. Baird	Neutral → Outperform
2024-03-20	Bestätigt	Needham	Buy
2024-02-20	Hochstufung	Mizuho	Neutral → Buy
2023-09-06	Eingeleitet	HSBC Securities	Hold
2023-07-19	Eingeleitet	Robert W. Baird	Neutral
2023-04-14	Eingeleitet	Mizuho	Neutral
2022-12-21	Eingeleitet	Barclays	Equal Weight
2022-04-06	Eingeleitet	Wolfe Research	Outperform
2022-02-24	Hochstufung	UBS	Neutral → Buy
2021-12-03	Eingeleitet	Goldman	Buy
2021-08-20	Bestätigt	Needham	Buy
2021-07-20	Hochstufung	Needham	Hold → Buy
2021-03-03	Herabstufung	Berenberg	Buy → Hold
2021-01-05	Herabstufung	Needham	Buy → Hold
2020-09-02	Eingeleitet	Robert W. Baird	Outperform
2020-06-26	Bestätigt	Needham	Buy
2019-10-30	Bestätigt	Needham	Buy
2019-02-28	Bestätigt	Needham	Buy
2018-11-28	Eingeleitet	UBS	Neutral
2018-08-02	Bestätigt	Needham	Buy
2018-06-08	Eingeleitet	Stifel	Buy
2018-05-31	Bestätigt	Needham	Buy
2018-02-28	Bestätigt	Needham	Buy

Alle ansehen

Livanova Plc Aktie (LIVN) Neueste Nachrichten

12:26 PM

(LIVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

12:26 PM

Mar 29, 2026

Aug Macro: Does LivaNova PLC stock benefit from AI growth2026 Earnings & Daily Volume Surge Signals - baoquankhu1.vn

Mar 29, 2026

Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN - MarketBeat

Mar 29, 2026

Mar 28, 2026

How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors - Sahm

Mar 28, 2026

Mar 27, 2026

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value - Benzinga

Mar 27, 2026

Mar 26, 2026

Should FDA Approval of aura6000 Sleep Apnea Therapy Require Action From LivaNova (LIVN) Investors? - Yahoo Finance

Mar 26, 2026

Mar 25, 2026

LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea - Insider Monkey

Mar 25, 2026

LivaNova Broadens OSA Treatment Options With FDA Clearance for aura6000 System - Bitget

Mar 25, 2026

LivaNova Expands OSA Care With FDA-Approved aura6000 System - Yahoo Finance

Mar 25, 2026

LivaNova to Announce First-Quarter 2026 Results - Business Wire

Mar 25, 2026

LivaNova PLC stock faces analyst scrutiny amid mixed ratings and modest growth outlook in medical de - AD HOC NEWS

Mar 25, 2026

Mar 24, 2026

LivaNova gains FDA premarket approval for Aura6000 for sleep apnea - msn.com

Mar 24, 2026

Mar 23, 2026

LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 23, 2026

Mar 22, 2026

FDA Approves Hypoglossal Nerve Stimulation Device for OSA - Medical Dialogues

Mar 22, 2026

Mar 20, 2026

FDA Approves LivaNova’s aura6000 Neurostimulator for OSA - Sleep Review

Mar 20, 2026

LivaNova aura6000 Obstructive Sleep Apnea treatment granted FDA premarket approval - Med-Tech Insights

Mar 20, 2026

LivaNova eyes 2027 launch of neural sleep apnoea therapy after FDA approval - Medical Device Network

Mar 20, 2026

LivaNova wins FDA approval for sleep apnea nerve device By Investing.com - in.investing.com

Mar 20, 2026

Mar 19, 2026

LivaNova Earns FDA Approval for Neurostim for Sleep Apnea - Medical Product Outsourcing

Mar 19, 2026

LivaNova wins FDA approval for sleep apnea nerve device - Investing.com

Mar 19, 2026

LivaNova gets FDA approval for sleep apnea device without collapse warning - StreetInsider

Mar 19, 2026

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea - The Joplin Globe

Mar 19, 2026

Mar 18, 2026

LivaNova Shares Gain 2% After Strong Q3 Results and Upgraded Full-Year Outlook - MSN

Mar 18, 2026

LivaNova PLC announced that its Aura6000 system has received premarket approval from the U.S. Food and Drug Administration (FDA). The device is designed to treat moderate to severe obstructive sleep apnea. - bitget.com

Mar 18, 2026

Patterns Watch: Is LivaNova PLC being accumulated by smart moneyMarket Performance Report & Momentum Based Trading Signals - baoquankhu1.vn

Mar 18, 2026

Short Interest in LivaNova PLC Rises By 18.0% - National Today

Mar 18, 2026

Mar 17, 2026

Short Interest in LivaNova PLC (NASDAQ:LIVN) Rises By 18.0% - MarketBeat

Mar 17, 2026

LIVN PE Ratio & Valuation, Is LIVN Overvalued - Intellectia AI

Mar 17, 2026

Algert Global LLC Cuts Stock Position in LivaNova PLC $LIVN - MarketBeat

Mar 17, 2026

Mar 16, 2026